Azithromycin Reduces S.aureus in Microbiome of Refractory chronic rhinosinusitis: Study
The sinonasal microbiome is believed to play an important role in the pathophysiology of refractory chronic rhinosinusitis (CRS). In the AZI-CRS study, researchers have reported azithromycin as a potential additional therapeutic option, as it significantly decreases Staphylococcus aureus abundance in the sinonasal microbiome in refractory CRS patients. The study findings were published in the journal International Forum of Allergy & Rhinology.
Chronic rhinosinusitis (CRS) is a heterogeneous condition
affecting the paranasal sinuses. It is one of the most common inflammatory diseases with an incidence and prevalence superior to 10%. Unfortunately, more than 30% of patients do not respond to standard medical and surgical treatment, thus continuously increasing the symptomatologic and socio-economic burden of this disease. Researchers of the Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Canada, hypothesized that the addition of azithromycin (AZI) to the treatment regimen of patients with refractory CRS failing conventional medico-surgical treatment will be beneficial in a symptomatologic and endoscopic level. Therefore, they conducted a study to evaluate changes in the microbiome following a 4‐month course of low‐dose azithromycin. Assessing microbiome alterations following such a treatment may help identify the underlying mechanisms of this drug.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.